ライフサイエンスコーパス: pain control

1 (cases) and 348 individuals with no chronic pain (controls).

2 e after surgery without negatively impacting pain control.

3 in vitro as a model system for post-surgical pain control.

4 uce such prescribing while ensuring adequate pain control.

5 on, the avoidance of opioids, and aggressive pain control.

6 ious difficulties for the use of opioids for pain control.

7 nts provide similar responses to amnesia and pain control.

8 ally scripted patient-physician dialog about pain control.

9 oles of NAAG, that promise rapid advances in pain control.

10 part because of patient-related barriers to pain control.

11 g the shift to end-of-life care and adequate pain control.

12 tter with M+H, in particular with respect to pain control.

13 vs OTCs plus opioids after Mohs surgery for pain control.

14 nt improvement and underwent enucleation for pain control.

15 r in patient satisfaction with postoperative pain control.

16 ld' stimuli provided a measure of descending pain control.

17 prefrontal cortex (PFC) produces descending pain control.

18 measurement and assessment of cancer-related pain control.

19 CYP2D6 activity may be associated with poor pain control.

20 delivery technology for long-term tumor and pain control.

21 poised to contribute to widespread systemic pain control.

22 ctive and reactive top-down processes during pain control.

23 as a safer opioid analgesic than morphine in pain control.

24 imary outcome was the median score of cancer pain control.

25 sent a therapeutic option for osteoarthritis pain control.

26 sign, increasing the focus on postoperative pain control.

27 P10 participate in Kv4.3-mediated mechanical pain control.

28 ces of misuse of opioid drugs prescribed for pain control.

29 erious obstacle to the provision of adequate pain control.

30 hould be tried before starting narcotics for pain control.

31 37]) were better than placebo for short-term pain control.

32 ggesting a spatial specificity of endogenous pain control.

33 y, and are excellent therapeutic targets for pain control.

34 of increasing the duration of postoperative pain control.

35 treatment groups did not use analgesics for pain control.

36 e of this structure for sleep regulation and pain control.

37 al management center of sleep regulation and pain control.

38 e its potential significance for therapeutic pain control.

39 e pharmacological target for female-specific pain control.

40 f prodynorphin and other downstream genes in pain control.

41 he spinal cord may be involved in endogenous pain control.

42 eric pumps, is recommended for postoperative pain control.

43 sedative regimen that did not include opiate pain control.

44 Primary outcome was time to stable pain control (3 consecutive days with pain <=3).

45 ces (78.7% vs. 72.4%; P < 0.001), and having pain controlled (51.3% vs. 46.7%; P < 0.001).

46 A pharmacological approach to pain control after cesarean delivery is often insufficie

47 to decrease opioid use without compromising pain control after cesarean delivery.

48 commonly used to provide acute postoperative pain control after major surgery.

49 timulation devices have proven effective for pain control after other surgical procedures, they have

50 esia may be superior to opioids for improved pain control along with increased patient satisfaction a

51 lower reported income; dissatisfaction with pain control also varied among study hospitals and by ph

52 al effects on access to opioids required for pain control among childhood cancer survivors.

53 Pain control among hospitalized patients is a national p

54 act infections, 3 (0.3%) readmissions (2 for pain control and 1 for mild confusion that resolved with

55 posomal bupivacaine did not provide improved pain control and did not reduce adjunctive opioid use co

56 PMS), a brain network involved in endogenous pain control and implicated in nociplastic pain conditio

57 ts, requiring dose escalation for persistent pain control and leading to overdose and fatal respirato

58 ductal gray (PAG), a structure important for pain control and learning in animal models.

59 superior patient experience through improved pain control and less narcotic use, without increased le

60 Analgesic techniques that provide optimal pain control and low side effect profiles with minimal o

61 This study aimed to assess current pain control and management for hospitalized adult patie

62 The objective of this study was to compare pain control and opioid consumption in critically ill pa

63 ive as oxycodone oral/enteral with regard to pain control and opioid consumption in the ICU.

64 ptor function, providing new perspectives in pain control and other pharmaceutical development target

65 Its use is essential in improving patient pain control and overall satisfaction as well as decreas

66 disease benefits patients in terms of better pain control and preservation of pancreatic function.

67 tigate disease progression, providing better pain control and preserving pancreatic function.

68 oid dose reduction while preserving adequate pain control and preventing mood disturbances, suggestin

69 y recurrent rectal cancer (LRRC) is limited, pain control and quality of life (QOL) are important par

70 asured by patient-centered outcomes, such as pain control and quality of life.

71 Local-regional nerve blocks improve pain control and reduce oversedation risks, but there ar

72 , 3-dimensional experiences that may improve pain control and reduce reliance on pharmacologic pain m

73 and reassurance regarding issues of safety, pain control and respect for patient preferences are imp

74 imal dosage of pregabalin and gabapentin for pain control and safety in these patients has not been w

75 d improve patient-centered outcomes, such as pain control and satisfaction.

76 We assessed data for pain control and skeletal-related events prospectively c

77 at minority patients do not receive adequate pain control and that better assessment of pain is neede

78 e, that the EP3 receptor provides endogenous pain control and that selective activation of EP3 recept

79 stopped or used no opioids owing to adequate pain control, and 16% to 29% of patients reported opioid

80 litis, first-line therapy is observation and pain control, and antibiotics should be initiated for pa

81 aster improvement in corneal clarity, better pain control, and avoidance of surgery in an inflamed ey

82 or to endoscopic interventions for long-term pain control, and early surgery (<3 years from symptom o

83 tomy hemorrhage, postoperative ED visits for pain control, and hospital length of stay without compro

84 Bowel rest, pain control, and intravenous fluids are the cornerstone

85 ence of skeletal-related events, measures of pain control, and patient-reported health-related qualit

86 n, minimization of organ dysfunction, active pain control, and promotion of patient autonomy).

87 otential to enhance quality of life, improve pain control, and reduce suffering for patients with can

88 resulting in accelerated recovery, improved pain control, and reduced hospital stay without compromi

89 ents, discovery of better anesthetic agents, pain control, and the evolution of perioperative care ar

90 onds to a conservative regimen of hydration, pain control, and the temporary discontinuation of the m

91 articularly colloid administration, adequate pain control, and treatment of pulmonary hypertension, m

92 lly stable, afebrile, oral intake tolerated, pain controlled, and follow-up confirmed).

93 herapy; a lack of evidence-based research on pain control; and misconceptions and prejudices about dr

94 included wound care education and supplies; pain control; approvals for nonhome postdischarge locati

95 ids, aerosolized beta agonists, and adequate pain control are necessary to reduce morbidity.

96 Although racial disparities in acute pain control are well established, the role of patient a

97 st a new, dramatically different approach to pain control, as all clinical therapies are focused excl

98 e brain regions mediating ANS and descending pain control associations.

99 rance of diet at 2.4 (vs 5.4) days, and oral pain control at 2.7 (vs 5.0) days (P < 0.0001).

100 d membrane stabilizing analgesics as well as pain control at the genetic level are discussed.

101 erapy, since it was associated with a modest pain control benefit in controlled trials.

102 lly significant difference in time to stable pain control between the arms, P = 0.667 (log-rank test)

103 Epidurals may be associated with superior pain control but this does not translate into improved r

104 s previously been implicated in this type of pain control, but the neurons and molecular circuits inv

105 blished intervention for ventral hernia, but pain control can be challenging.

106 nd other relevant outcome domains, including pain control, cardiac complications, and overall recover

107 ediated, noxious stimulus-induced endogenous pain control circuit.

108 yndromes can modulate activity in endogenous pain control circuits and that this effect is sympathoad

109 syndromes on the function of the endogenous pain control circuits at which these drugs act to produc

110 The main outcome measure was pain control combined with change of toxicity, as measur

111 g) with hydrocodone (5 mg) results in better pain control compared to ibuprofen used alone.

112 ritoneal wound catheters provided comparable pain control compared with active controls, such as epid

113 c cancer surgery without adversely affecting pain control, complications, or recovery.

114 t delivered to patients, and the "subjective pain control" condition, during which the intensity of s

115 thologic fracture, radiation for fracture or pain control, conservatively treated pathologic fracture

116 nomy (91.6%) and dignity (78.7%); inadequate pain control contributed in 25.2% of cases.

117 Pain control, delirium, and pressure ulcer prevention ar

118 powerful pain relievers; however, over time, pain control diminishes as analgesic tolerance develops.

119 e from the use of a snail toxin to develop a pain control drug, metabolites from a sea squirt to deve

120 Mu opioid receptors (MORs) are central to pain control, drug reward, and addictive behaviors, but

121 ed as an adjunct procedure for postoperative pain control during elective abdominal aortic aneurysm (

122 t and process of care factors that influence pain control during FOB.

123 Inequalities in access to pain control during procedures were reported by parents

124 s patient global assessment of the method of pain control during the first 24 hours.

125 is to deliver fentanyl provided postsurgical pain control equivalent to that of a standard intravenou

126 Addressing pain control expectations before discharge may help redu

127 Because pain-control failure is highly detrimental, surgeons may

128 nd thermosetting agents may be effective for pain control for scaling and root planing and may offer

129 discontinuation rate for lack of acceptable pain control (from 34% to 4% with CR and from 31% to 19%

130 ell as changes in quality of life, perceived pain control, functional status, analgesics, and physici

131 Acute pain control has advanced dramatically and is now a fiel

132 ion of economic and humanitarian benefits of pain control has prompted worldwide attention from profe

133 els, with relevance to mechanisms underlying pain control, hypertension and anxiety.

134 In intergroup comparisons regarding pain control, ibuprofen showed better effects than place

135 domains: home independence, social support, pain control, immediate, and overall surgical impact.

136 ort the safety of early opioid analgesia for pain control in AP, although residual confounding cannot

137 With increased emphasis on pain control in children, it is likely that iatrogenic w

138 ous bisphosphonate, pamidronate disodium, on pain control in metastatic prostate cancer patients.

139 eutic approaches have substantially improved pain control in past years.

140 mmended as routine, supplemental therapy for pain control in patients after elective cesarean deliver

141 gesia was observed to be superior to PCA for pain control in patients undergoing open hepatic resecti

142 Thus, research and training on pain control in sickle cell disease are needed to parall

143 ystem for the discovery of new therapies for pain control in women are also discussed.

144 Nonsurgical options for pain control included behavior modification (smoking ces

145 Conservative debridement of necrotic bone, pain control, infection management, use of antimicrobial

146 management of lines, tubes, and drains, and pain control interventions.

147 order, anesthesia type, first or second eye, pain control, intra-operative heart rate and blood press

148 Pain control is among the most important healthcare serv

149 Pain control is as effective as epidural analgesia, but

150 Although adequate postoperative pain control is critical to patient and surgeon success,

151 kers have demonstrated that this approach to pain control is feasible.

152 Pain control is of uttermost importance and stimulus con

153 The clinical efficacy of opiates for pain control is severely limited by analgesic tolerance

154 ing corticosteroids to stronger opioids when pain control is the primary objective.

155 t whether they participate in Kv4.3-mediated pain control is unknown.

156 tinues for as long as the opiate is used for pain control, is constipation.

157 e, and offered an alternative to opioids for pain control.Keywords: Ablation Techniques, Metastases,

158 Optimal pain control may improve quality of life (QOL) for these

159 l advance in the understanding of endogenous pain control mechanisms by bridging the gap between prev

160 Endogenous pain control mechanisms have long been known to produce

161 In particular, endogenous pain control mechanisms, such as stress-induced analgesi

162 To investigate alternate pain control mechanisms, we explored cholinergic signali

163 rating theatre and anaesthetic technique and pain-control methods were standardised.

164 ensuring a calming environment and adequate pain control, minimizing benzodiazepines and anticholine

165 laparoscopy appears to improve postoperative pain control modestly, especially when given into the pe

166 thesia-related claims were due to inadequate pain control (n = 2), ocular movement resulting in capsu

167 n directed to supportive care including oral pain control, nutritional support, infection treatment a

168 (eg, antiviral therapy, antibacterials, and pain control) occur in up to 40% of patients and include

169 early or first aid use of aspirin for chest pain; control of life-threatening bleeding through the u

170 use of an easy, inexpensive, and achievable pain control option.

171 or second eye surgery affect intra-operative pain control or are correlated with type of anesthesia m

172 age if pharmacotherapy is not sufficient for pain control or has intolerable adverse effects or contr

173 on did not affect quality of life, perceived pain control, or functional status.

174 sthetics have been shown to provide improved pain control over alternative strategies and allow PRK-a

175 ue strategies offered limited improvement in pain control over control treatments.

176 as a possible benefit of M+H with respect to pain control over hydrocortisone alone.

177 us patient-controlled analgesia (IV-PCA) for pain control over the first 48 hours after hepatopancrea

178 prove adherence and, ultimately, to optimize pain control over time.

179 noxious inhibitory control (DNIC) endogenous pain control pathways and lumber norepinephrine and sero

180 Secondary outcomes include efficacy of pain control, patient satisfaction, and refill requests.

181 tion (anterior cingulate cortex); descending pain control (periaqueductal grey); and an extensive net

182 -making discussions to determine the optimal pain control plan for each individual.

183 ial tested the effectiveness of the PRO-SELF Pain Control Program compared with standard care in decr

184 application of sustainable patient-centered pain control protocols.

185 IDDSs improved clinical success in pain control, reduced pain, significantly relieved commo

186 or dying nursing home residents by improving pain control, reducing hospitalization, and reducing use

187 e of high doses of opioids and sedatives for pain control, regardless of the risk that they will hast

188 Although various pain control regimens exist, patient preferences for acu

189 These findings suggest that multimodal pain control regimens that are associated with optimized

190 tial patient-friendly therapeutic option for pain control related to inflammatory disorders of the TM

191 Pain control remained significantly improved after 36 mo

192 od than parenteral opioids for postoperative pain control remains controversial.

193 primarily of alcohol and smoking cessation, pain control, replacement of pancreatic insufficiency, o

194 Ineffective pain control results in many postoperative complications

195 Interventions to improve pain control should consider modifying donor behavioral

196 survey, patient-reported opioid consumption, pain control, sleep disturbance, anxiety, and depression

197 This pain control strategy may help achieve dose escalation w

198 parate experiments directed at postoperative pain control, subcutaneous administration of RTX transie

199 us opioidergic circuits along the descending pain control system.

200 e demonstrated to offer significantly better pain control than comparison treatments.

201 ents), preperitoneal catheters led to better pain control than subcutaneous catheters.

202 ation and a compensatory state of endogenous pain control that is maintained long after tissue healin

203 Strategies to improve pain control through behavioral modification, endoscopic

204 ip of level of pain and dissatisfaction with pain control to demographic, psychological, and illness-

205 d for greater focus on optimal postoperative pain control to minimize opioid use and improve outcomes

206 Pain and satisfaction with pain control varied significantly among study sites, eve

207 Adequate postoperative pain control was achieved using nonopioid interventions.

208 Pain control was compared between a propensity score mat

209 Pain control was excellent in 36% of patients, but 10% c

210 In the 15-year long-term follow-up, the pain control was good and comparable between both groups

211 confounding variables, dissatisfaction with pain control was more likely among patients with more se

212 Pain control was superior in the ERAS group, with consis

213 th utility values for the queried aspects of pain control were calculated.

214 Patient factors associated with excellent pain control were excellent health (versus poor health,

215 fter 24 hours of treatment for the method of pain control were given by 73.7% of patients (233/316) w

216 ss of care factors associated with excellent pain control were not being bothered by scope insertion

217 s associated with pain and satisfaction with pain control were patient demographics and those variabl

218 overall preemptive effects on postoperative pain control when compared with ibuprofen.

219 act immune system plays an essential role in pain control, which is important for the understanding o

220 iteal sciatic nerve block provides effective pain control, which results in excellent patient and ope

221 Efforts to fine tune pain control while alleviating the side effects of drugs

222 advent of additional vaccines, attention to pain control will take on increasing urgency.

223 oved pain relief in patients with suboptimal pain control with a monotherapy.

224 cide whether or not to receive narcotics for pain control would result in fewer unnecessary opioid pr

225 idable, stemming primarily from insufficient pain control, wound checks, postoperative complications,

226 for a patient after surgery should consider pain control; wounds, ostomies, tubes, and drains; and t